Wednesday, October 18, 2017 3:01:13 PM
1. They are targeting turning COLD tumours into HOT tumours.
2. Checkpoint inhibitors working alone turn about 10% of COLD tumours into HOT tumours.
3. Adding HS-110 to checkpoint inhibitors turned about 60% of COLD tumours into HOT. This data was based one a very small sample but this data supplemented by additional patients are the basis for receiving a Type C meeting with the FDA to seek guidance as to the approval path for HS-110.
4.HS-110, HS-120 (HS-110 + OX40), PTX-35 and PTX-15 are "all in manufacture". CPRIT grant of $15 million will cover the cost of trials of several combinations of these drugs with checkpoint inhibitors
5. HS-110 plus Opdivo trials have now begun in 8 trial centers.
6. The COG for CAR-T drugs is anywhere from $35,000 to $50,000 for a course of treatment. The COG for HS-110 is under $1,000 for an entire course of treatment(because it is of-the-shelf). Good news for cancer patients and governments looking for reasonable prices for cancer treatments!
"The refusal of the real is the number one dogma of our time" Rene Girard
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM